Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2002-11-05
2008-11-04
Devi, S. (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387900, C530S387300, C530S864000, C530S865000, C530S866000, C530S867000, C530S809000
Reexamination Certificate
active
07446182
ABSTRACT:
A composition and method for treating a host having or at risk of infection byBacillus anthracisusing an affinity matured antibody or portion thereof derived from a monoclonal antibody.
REFERENCES:
patent: 5601823 (1997-02-01), Williams et al.
patent: 6329156 (2001-12-01), Cirino et al.
patent: 6916474 (2005-07-01), Harvey et al.
patent: 2005/0106647 (2005-05-01), Harvey et al.
patent: 2005/0267294 (2005-12-01), Harvey et al.
patent: WO 99/36569 (1999-07-01), None
patent: WO 2005/023177 (2005-03-01), None
Maynard et al. In: Abstracts of Papers of 216th National Meeting of the ACS, Boston, Massachusetts, #212, BIOT, Aug. 23-27, 1998.
Rosovitz et al. J. Biol. Chem. 278: 30936-30944, May 2003.
Harvey et al. PNAS 101: 9193-9198, Jun. 22, 2004.
Maynard et al. Nature Biotechnol. 20: 597-601, Jun. 2002.
Bradley et al., “Identification of the cellular receptor for anthrax toxin,”Nature, 414:225-229, 2001.
Bull and Parrish, “A binding contract for anthrax,”Science, 297:201-202, 2002.
Chen et al., “Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric sceening,”Nature Biotechnology, 19:537-542, 2001.
Daugherty et al., “Quantitative analysis of the effect of the mutation frequency on the affinity maturation of antibodies,”Proc. Natl. Acad. Sci., USA, 97:2029-2034, 2000.
Ezzell et al., “Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective anitgen and lethal factor components ofBacillus anthracistoxin,”Infect. Immun., 45:761-777, 1984.
Ivins et al., “Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin,”Applied and Environmental Microbiology, 55:2098-2100, 1989.
Keller and Stiehm, “Passive immunity in prevention and treatment of infectious diseases,”Clin. Microbiol. Reviews, 13:602-614, 2000.
Krebber et al., “Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system,”J. Immunol. Methods, 201:35-55, 1997.
Leppla, “Anthrax toxin,” Chapter 19 In:Handbook of Experimental Pharmacology, 145:445-472, 2000.
Little et al., “Characterization of lethal factor binding and cell receptor binding domains of potective antigen ofBacillus anthracisusing monoclonal antibodies,”Microbiology, 142:707-715, 1996.
Little et al., “Passive protection by polyclonal antibodies againstBacillus anthracisinfection in guinea pigs,”Infection and Immunity, 65:5171-5175, 1997.
Little et al., “Production and characterization of monoclonal antibodies to the protective antigen component ofBacillus anthracistoxin,”Infect. Immun., 56:1807-1813, 1988.
Maynard et al., “Production against anthrax toxin by recombinant antibody fragments correlates with antigen affinity,”Nature Biotechnology, 20:597-601, 2002.
Mourez et al., “Designing a polyvalent inhibitor of anthrax toxin,”Nature Biotechnology, 19:958-961, 2001.
Pitt et al., “In vitro correlate of immunity in a rabbit model of inhalational anthrax,”Vaccine, 19:4768-4773, 2001.
Sellman et al., “Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax,”Science, 292:695-697, 2001.
Singh et al. “A dominant negative mutant ofBacillus anthracisprotective antigen inhibits anthrax toxin in vivo,”J. of Biol. Chem., 276:22090-22094, 2001.
Turnbill et al., “Antibodies to Anthrax Toxin in Humans and Guinea Pigs and Their Relevance to Protective Immunity,” Abstract,Med. Microbiol. Immunol., 177:293-303, 1988.
Chen and Okayama, “High-efficiency tranformation of mammalian cells by plasmid DNA,”Mol. Cell Biol., 7(8):2745-2752, 1987.
Chen et al., “In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site,”Protein Eng., 12:349-352, 1999.
Cirino et al., “Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors,”Infection and Immunity, 67:2957-2963, 1999.
Creighton,Protein Structure: A Practical Approach, p. 184-186, 1994.
Creighton,Proteins: Structures and Molecular Properties, p. 314-315, 1984.
Georgiou et al., “Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines,”Nat. Biotechnol., 15:29-34, 1997.
Hayhurst and Georgiou,. “High throughput isolation,”Curr. Opin. Chem. Biol., 5:683-689, 2001.
Hayhurst and Harris, “Escherichia coliSkp chaperone coexpression improves solubility and phage display of single-chain antibody fragments,”Protein Expr. Purif., 15:336-343, 1999.
Hayhurst, “Improved expression characteristics of single-chain Fv fragments when fused downstream of theEscherichia colimaltose-binding protein or upstream of a single immunoglobulin-constant domain,”Protein Expr. Purif., 18:1-10, 2000.
Hoess, “Protein design and phage display,”Chem. Rev., 101:3205-3218, 2001.
Nosoh et al.,Protein Stability and Stabilization through ProteinEngineering, Chapter 7, p. 197, 1991.
Wittrup, “The single cell as a microplate well,”Nat. Biotechnol., 18:1039-1040, 2000.
Castillo et al., “T7 displayed peptides as targets for selecting peptide specific scFvs from M13 scFv display libraries,”J. Immunol. Methods, 257:117-122, 2001.
Knappik et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomizied with trinucleotides,”J. Mol. Biol., 296:57-86, 2000.
Stemmer, “Rapid evolution of a protein in vitro DNA shuffling,”Nature, 370:389-391, 1994.
Walroy et al., “Comparison of four serological methods for the detection of diphtheria anti-toxin antibodies,”J. Immunol. Methods, 245:55-65, 2000.
Georgiou George
Iverson Brent L.
Maynard Jennifer A.
Board of Regents , The University of Texas System
Devi S.
Fulbright & Jaworski L.L.P.
LandOfFree
Recombinant antibodies for the detection and neutralization... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant antibodies for the detection and neutralization..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant antibodies for the detection and neutralization... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4021697